Management claims the company has a massive $40 trillion total addressable market, which includes the economic value of ...
40m
Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...
Stoke Therapeutics Inc (STOK) ended Q3 2026 with $358.8 million in cash to fund operations into early 2028, while advancing its Phase 3 EMPEROR study toward top-line data expected in Q3 2027.
This family-friendly watchlist includes gentle scares, fantasy adventures and monsters, with picks for young children, teens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results